Gary Gilliland

2.7k total citations · 1 hit paper
19 papers, 1.8k citations indexed

About

Gary Gilliland is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Gary Gilliland has authored 19 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 9 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Gary Gilliland's work include Chronic Myeloid Leukemia Treatments (10 papers), Acute Myeloid Leukemia Research (9 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Gary Gilliland is often cited by papers focused on Chronic Myeloid Leukemia Treatments (10 papers), Acute Myeloid Leukemia Research (9 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Gary Gilliland collaborates with scholars based in United States, Switzerland and Australia. Gary Gilliland's co-authors include H. Franklin Bunn, Sean Perrin, K L Blanchard, Ayalew Tefferi, Shin-ichi Mizuno, Siamak Jabbarzadeh‐Tabrizi, Goichi Yoshimoto, Hiroaki Niiro, Koji Nagafuji and Hiromi Iwasaki and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Gary Gilliland

17 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction.

1990 1.3k citations Gary Gilliland, Sean Perrin et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary Gilliland United States	11	979	355	234	186	176	19	1.8k
K L Blanchard United States	8	988 1.0×	259 0.7×	214 0.9×	186 1.0×	153 0.9×	9	1.8k
Fabíola Attié de Castro Brazil	23	675 0.7×	289 0.8×	338 1.4×	92 0.5×	170 1.0×	78	1.4k
Tzvete Dentchev United States	28	1.0k 1.0×	210 0.6×	695 3.0×	261 1.4×	260 1.5×	44	2.3k
Sophia Derdak Austria	21	800 0.8×	334 0.9×	630 2.7×	141 0.8×	272 1.5×	58	1.9k
Russel E. Kaufman United States	26	1.0k 1.1×	376 1.1×	510 2.2×	206 1.1×	238 1.4×	62	2.2k
Noriko Hosoya Japan	22	1.2k 1.2×	255 0.7×	167 0.7×	232 1.2×	353 2.0×	53	2.2k
C. Howard Barton United Kingdom	20	523 0.5×	268 0.8×	353 1.5×	303 1.6×	143 0.8×	29	1.5k
Clarissa Uhlar United States	15	934 1.0×	538 1.5×	457 2.0×	177 1.0×	551 3.1×	35	1.9k
Bernard Renaux Canada	19	524 0.5×	387 1.1×	250 1.1×	52 0.3×	89 0.5×	29	1.3k
Adam Rosenthal United States	21	672 0.7×	387 1.1×	209 0.9×	84 0.5×	283 1.6×	59	1.4k

Countries citing papers authored by Gary Gilliland

Since Specialization

Citations

This map shows the geographic impact of Gary Gilliland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Gilliland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Gilliland more than expected).

Fields of papers citing papers by Gary Gilliland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Gilliland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Gilliland. The network helps show where Gary Gilliland may publish in the future.

Co-authorship network of co-authors of Gary Gilliland

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Gilliland. A scholar is included among the top collaborators of Gary Gilliland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Gilliland. Gary Gilliland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Cucolo, Lisa, Jingya Qiu, Max Klapholz, et al.. (2020). Tumor RIPK1 signaling mediates intrinsic and extrinsic mechanisms of resistance to immune checkpoint blockade therapy. The Journal of Immunology. 204(1_Supplement). 241.29–241.29.

Rivera-Muñoz, Paola, Aurélie Siret, Cécile K. Lopez, et al.. (2018). Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models. Blood Advances. 2(13). 1616–1627. 10 indexed citations

Blank, Rebecca M., Ronald J. Daniels, Gary Gilliland, et al.. (2017). A new data effort to inform career choices in biomedicine. Science. 358(6369). 1388–1389. 33 indexed citations

Samatar, Ahmed A., Erick J. Morris, Sharda Jha, et al.. (2013). Abstract 2343: A novel ERK inhibitor is active in models of acquired resistance to BRAF and MEK inhibitors.. Cancer Research. 73(8_Supplement). 2343–2343.

Zhang, Weisheng, Brian B. Haines, Clay L. Efferson, et al.. (2012). Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors. Translational Oncology. 5(6). 422–429. 21 indexed citations

Yoshimoto, Goichi, Toshihiro Miyamoto, Siamak Jabbarzadeh‐Tabrizi, et al.. (2009). FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD–specific STAT5 activation. Blood. 114(24). 5034–5043. 200 indexed citations

Weisberg, Ellen, Johannes Roesel, Guido Bold, et al.. (2008). Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood. 112(13). 5161–5170. 28 indexed citations

Weisberg, Ellen, Andrew L. Kung, Renee D. Wright, et al.. (2007). Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Molecular Cancer Therapeutics. 6(7). 1951–1961. 66 indexed citations

Moellering, Raymond E., Melanie Cornejo, Michael K. Hancock, et al.. (2007). Direct Inhibition of the Notch Transactivation Complex with Synthetic Constrained Peptides in T-Cell Acute Lymphoblastic Leukemia.. Blood. 110(11). 2819–2819. 3 indexed citations

10.

Loriaux, Marc, Ross L. Levine, Jeffrey Tyner, et al.. (2007). High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia.. Blood. 110(11). 886–886. 4 indexed citations

11.

Kuchenbauer, Florian, Susanne Schnittger, Thomas Look, et al.. (2006). Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1‐ETO. British Journal of Haematology. 134(6). 616–619. 47 indexed citations

12.

Mueller, Beatrice U., Thomas Pabst, Péter Hauser, et al.. (2006). Mutations of the transcription factor PU.1 are not associated with acute lymphoblastic leukaemia. British Journal of Cancer. 94(12). 1918–1920. 4 indexed citations

13.

Tefferi, Ayalew & Gary Gilliland. (2006). Classification of chronic myeloid disorders: From Dameshek towards a semi-molecular system. Best Practice & Research Clinical Haematology. 19(3). 365–385. 28 indexed citations

14.

Mestan, Jürgen, Josef Brueggen, Doriano Fabbro, et al.. (2005). In vivo activity of AMN107, as selective Bcr-Abl kinase inhibitor, in murine leukemia models. Journal of Clinical Oncology. 23(16_suppl). 6522–6522. 1 indexed citations

15.

Huntly, Brian J.P., Kenji Deguchi, Benjamin J. Lee, et al.. (2004). MOZ-TIF2, but Not BCR-ABL, Confers Properties of Leukemic Stem Cells to Committed Murine Hematopoietic Progenitors.. Blood. 104(11). 62–62. 1 indexed citations

16.

Arepally, Gowthami M., Timothy R. Rebbeck, Woo‐Joo Song, et al.. (1998). Evidence for Genetic Homogeneity in a Familial Platelet Disorder With Predisposition to Acute Myelogenous Leukemia (FPD/AML). Blood. 92(7). 2600–2602. 26 indexed citations

17.

Legare, Robert D. & Gary Gilliland. (1995). Myelodysplastic syndrome. Current Opinion in Hematology. 2(4). 283–292. 12 indexed citations

18.

Gilliland, Gary, et al.. (1990). Multiple clones with (3;21) translocation in a case of Ph-positive chronic myelogenous leukemia during relapse after allogeneic bone marrow transplantation. Cancer Genetics and Cytogenetics. 47(1). 55–60. 10 indexed citations

19.

Gilliland, Gary, Sean Perrin, K L Blanchard, & H. Franklin Bunn. (1990). Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction.. Proceedings of the National Academy of Sciences. 87(7). 2725–2729. 1286 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact